Dr. Lin studied medicine at NTU. Following this, he completed resident training in VGH Taipei and GI fellowship in Chang-Gung Memorial Hospital-Linkuo. Dr. Lin is currently a Professor since 2007 at CGMH and Chang Gung University.

Dr. Lin is one of the pioneers of RFA for liver tumors in Taiwan. So far, 9 international doctors have studied RFA under the teaching by Dr. Lin. He has published 120 papers including Gastroenterolgy, Hepatology, Gut, Journal of Hepatology, and Cancer. Dr. Lin has 4 papers (Hepatology 1999 and Gastroenterology 2004, Gut 2005 and J Hepato 2007) ranked as the highly cited papers. Dr. Lin has given 110 invited lectures in the area of his expertise including Philippine Liver Society Annual Meeting 2020, APASL (2006-9, 2012-13, 2019-20), APDW (2007, 09), Annual MW Surg Meeting Jpn (2008, 09), Kobe HCC symposium (2009), APPLE (2010-15,2019), 2013 Korea-Japan Image-guide Ablation Meeting, Japan JSH 2012, HK IDD 2011, HK IR Symposium 2009, South East Asian conference (2008, 2010, 2012), Singapore GI Annual Meeting 2009, ACTA 2014-2016, 4th International Kyoto Liver Cancer Symposium 2014, Mongolia DDW 2014, Oncology Multi-disciplinary Approach Symposium, Kuala Lumpur 2014, Quarter century’s contribution to liver research by TASL 2015, APAITO 2016, University of Tokyo 10,000 RFA meeting 2017, Tokyo Hepatitis Forum 2019 and ISVHLD 2021. Dr. Lin is serving as a referee of journals including Gastroenterology, Hepatology, Gut, J Hepatol, Ann Surg, Liver Cancer, Cancers et al. His research interest includes diagnosis (cytology and CEUS) and treatment (RFA, target and immune checkpoint inhibitor) of hepatoma and antiviral therapies for hepatitis B/C. 1960-2022 WORLD TOP 2% SCIENTIST (2021-10-20 Stanford’s university report).